A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
10/2006
10/25/2006	EP1714969A2 Immunostimulatory nucleic acid molecules
10/25/2006	EP1713514A2 Drugs and gene carrier particles that rapidly move through mucous barriers
10/25/2006	EP1713511A1 Therapeutic agent for treatment of cancer comprising human apolipoprotein (a) kringles lk68 or lk8 genes as effective ingredient, and method for treating cancer using the same
10/25/2006	EP1713507A2 Adept or gdept production of acetaldehyde
10/25/2006	EP1713337A2 Modulation of line-1 reverse transcriptase
10/25/2006	EP1670948A4 GENE MODULATION BY RB2/p130 EXPRESSION
10/25/2006	EP1313476B1 Sgk3 used as diagnostic and therapeutic target
10/25/2006	EP1097167B1 Neurotrophic growth factor
10/25/2006	EP0957902B1 System for genetically treating cardiac conduction disturbances
10/25/2006	CN1852917A Synergisitic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
10/25/2006	CN1852741A Compounds and methods for downregulating the effects of TGF-beta
10/25/2006	CN1852690A Medicament conveying system
10/25/2006	CN1850977A Soluble colibacillus expression plasmid and its use
10/25/2006	CN1850857A Rana grahami propyl sperm peptide, gene and variant and its pharmaceutical use
10/25/2006	CN1850279A PcrDNA vaccine, and its preparing method and use
10/25/2006	CN1850278A Polyethyleneglyol modified recombinant human B lymphocyte stimulating factor and its preparing method
10/25/2006	CN1850269A Function of GPR39 gene for central nervous system of mammal and its use
10/25/2006	CN1281758C Eukaryotic expression vector of ER-detented IV collagenase cellular antibody gene
10/25/2006	CN1281753C Monoclonal antibody CAb-1 heavy and light chain variable region gene of human carcinoma of large intestine, and its uses
10/25/2006	CN1281752C Carcinoma of esophagus related gene-2 and use of coding protein thereof
10/25/2006	CN1281748C Gene of IL-12 p40 subunit mutated for improving activity of IL-12 and use thereof for DNA vaccine adjuvant
10/25/2006	CN1281747C i(Ehrlichia canis) 120-KDa immunodominant antigenic protein and gene
10/25/2006	CN1281279C Small interference ribonucleic acid molecule for epidermal growth facor gene and its use
10/25/2006	CN1281278C Gene-carrying micro-bublle of target transfergene, its preparation method and use
10/25/2006	CN1281277C DNA vaccine for preventing influenza virus infection
10/25/2006	CN1281276C Virus vector for transferring gene into renal cells
10/24/2006	US7125975 Derivatized oligonucleotides having improved uptake and other properties
10/24/2006	US7125969 Diagnosis; prognosis; transcription factors
10/24/2006	US7125957 VPR mutant protein and its encoding gene having apoptosis-inducing action
10/24/2006	US7125902 Anticancer agents for, lungs, leukemia and ovarian cancer or prostate glands
10/24/2006	US7125860 Cross-linked derivatives of hyaluronic acid
10/24/2006	US7125858 Hyaluronic acid in the treatment of cancer
10/24/2006	US7125720 live vector vaccine; removal of sole dependence on catalytic balanced lethal maintenance systems; plasmid partition system prevents random segregation; enhanced inheritance and stability; genetic engineering; antibiotic resistance
10/24/2006	US7125718 Method for introducing and expressing genes in animal cells, and bacterial blebs for use in same
10/24/2006	US7125717 Metabolically activated recombinant viral vectors and methods for their preparation and use
10/24/2006	US7125714 Progenitor cell materials and methods
10/24/2006	US7125712 DNA segment from a BIV genome; a packaging sequence to package RNA into virions; a first promoter operably linked to the DNA segment; d) a transgene operably linked to a second promoter and deletion of vpw, vpy and tat from the construct
10/24/2006	US7125706 Method for the production and purification of adenoviral vectors
10/24/2006	US7125676 Modified human sodium channel type 1 alpha subunit (SCN1A) nucleic acid that encodes an SCN1A voltage-gated sodium channel polypeptide that regulates Na+ ion membrane permeation; identifying a sodium channel modulator
10/24/2006	US7125675 Method for inhibiting tumor invasion or spreading in a subject
10/24/2006	US7125568 Lipophilic drug compositions
10/24/2006	US7125566 Particulate drug-containing products and method of manufacture
10/24/2006	US7125557 Isolated haemocyanin polypeptide having a specific amino acid sequence recombinantly expressed in a host cell, wherein the glycosylation pattern is different from naturally occurring KLH from Megathura crenulata; may be bonded to a virus, bacteria, DNA, carbohydrate, peptide or glycoprotein
10/24/2006	US7125556 Nucleic acid molecule comprising a nucleic acid sequence coding for a haemocyanin
10/24/2006	US7125551 Compound for use inthe diagnosis and treatment of cancer, viral, asthmatic, autoimmune, organ transplant rejection and infections
10/24/2006	US7125549 Synergistic combination of two adenoviral vectors that are replication incompetent cotranscomplements of each other and one is recombinant 1014; enhances both gene delivery and gene expression of genetic sequences contained within the vector.
10/24/2006	US7125548 Nucleotide sequences coding microorganismal cistron; for use in detection of microoganismal infection
10/19/2006	WO2006110843A2 Engineered deremal tissue particles and transplantation methods
10/19/2006	WO2006110813A2 Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
10/19/2006	WO2006110689A2 Method of increasing the function of an aav vector
10/19/2006	WO2006109044A2 Selective modulation of tumour necrosis factor receptors in therapy
10/19/2006	WO2006108474A2 Use of a galectin-1-trageted rnai-based approach for the treatment of cancer
10/19/2006	WO2006050026A3 Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
10/19/2006	WO2006033689A8 Aav mediated gene delivery to cochlear cells
10/19/2006	WO2005104790A3 Treatment of muscular dystrophy with mobilized peripheral blood pluripotent cells
10/19/2006	WO2005092924A8 Rab9a, rab11a, and modulators thereof related to infectious disease
10/19/2006	WO2005089252A3 Methods and compositions for the treatment of obesity
10/19/2006	WO2004020605A3 Circular nucleic acid vectors, and methods for making and using the same
10/19/2006	WO2003031932A3 Methods and compositions for detecting colon cancers
10/19/2006	US20060236413 Transposon-based targeting system
10/19/2006	US20060235201 Enduring T cell response
10/19/2006	US20060234973 Inhibiting E2F1 polypeptide expression; restenosis
10/19/2006	US20060234972 airway hyperresponsiveness, and/or pulmonary inflammation; respiratory system disorders; aerosol
10/19/2006	US20060234971 Calpains as targets for inhibition of prion propagation
10/19/2006	US20060234970 Corneal administration; RNA interference; glaucoma, diabetic retinopathy
10/19/2006	US20060234969 Compositions and methods for inhibiting inflammation of vessel walls and formation of neointimal hyperplasia
10/19/2006	US20060234968 Inhibition of the cd95 ligand/receptor system for the treatment of neurological disorders and injuries
10/19/2006	US20060234967 Human protooncogene and protein encoded therein
10/19/2006	US20060234966 Method for expressing inducible rna [in cells, nucleic acid molecules therefor and cells transformed by said molecules
10/19/2006	US20060234965 Novel full-length genomic rna of Japanese encephalitis virus, infectious jev cdna therefrom, and use thereof
10/19/2006	US20060234964 nucleatide sequences that code transforming growth factor beta (TGF- beta), for the treatment of autoimmune diseases such as inflammatory bowel disease
10/19/2006	US20060234958 Process of increasing cellular production of biologically active compounds
10/19/2006	US20060234937 Modulation of angiogenesis
10/19/2006	US20060234930 Use of dg008,dg065,dg210 or dg239 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
10/19/2006	US20060234926 Nucleic acid ligands and uses therefor
10/19/2006	US20060234924 A kit for screening a compound or its salt that promotes or inhibits the activity of the proteins; drug screening for hyperlipemia, arteriosclerosis, genital, digestive, respiratory diseases, renal, pancreatic, central nerve, respiratory, inflammatory, rheumatoid diseases and diabetic neurosis
10/19/2006	US20060234344 Protein kinases
10/19/2006	US20060234342 Human DNA topoisomerase I alpha
10/19/2006	US20060234339 Method of expressing protein having unnatural amino acid integrated thereinto
10/19/2006	US20060234292 Methods of diagnosing and treating diabetes and insulin resistance
10/19/2006	US20060234290 Novel genes and expression products therefrom
10/19/2006	US20060234286 Human paris-1 antigen and nucleic acids: diagnostic and therapeutic uses
10/19/2006	US20060234271 Methods for the diagnosis and treatment of metastatic prostate tumors
10/19/2006	US20060234239 An oligonucleotide targeted to (hybridizing with) a nucleic acid molecule encoding human insulin like growth factor I receptor; treatment of proliferative and inflammatory skin disorders and cancer
10/19/2006	US20060234227 Helix-hairpin-helix motifs to manipulate properties of dna processing enzymes
10/19/2006	US20060234224 Method and nucleic acids for the analysis of colon cell proliferative disorders
10/19/2006	US20060233857 Degradable elastomeric network
10/19/2006	US20060233839 Novel compounds
10/19/2006	US20060233835 Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
10/19/2006	US20060233832 Composition for the prophylaxis and treatment of HBV infections and HBV-mediated diseases
10/19/2006	US20060233827 85kDa neisserial antigen
10/19/2006	US20060233818 Organic compounds
10/19/2006	US20060233807 Novel therapies and methods of screening for therapeutic compounds
10/19/2006	US20060233806 Removal promoters and inhibitor for apoptosis cells in vivo
10/19/2006	US20060233801 TGF- beta binding proteins which can be utilized to increase bone mineralization, and thus may be utilized in treating osteopenia, osteoporosis and bone fractures
10/19/2006	US20060233796 Method of modulating memory effector T-cells and compositions
10/19/2006	US20060233792 novel tumor necrosis factor receptor (TRAIN-R) for treating inflammatory bowel disease and arthritic condition; antiinflammatory agents
10/19/2006	US20060233787 Human cd3-specific antibody with immunosuppressive properties
10/19/2006	US20060233771 Methods for promoting dopaminergic neuronal development by using ng4a-subfamily and wnt-ligands
10/19/2006	US20060233770 a human cell line, which lacks major histocompatibility class I (MHC-I) and class II (MHC-II) antigens, has been modified to comprise and express a nucleotide sequence encoding an immunomodulator, and a nucleotide sequence encoding an antigen of Epstein-Barr virus

1 ... 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 ... 870